Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

Actually it was electric cattle prods - the farmers down in Dorset aren't as backward as they're made out to be.

LOL!
arrr don't be messin wiv this ere new fangled lectric. It be witchcraft I'll tell thee.

So its confirmed - Gartmore WERE buying the shares from the likes of the above shortsighted ones.

SAR 3 - Osmetech plc

FORM SAR 3

DISCLOSURE OF ACQUISITIONS

(Rule 3 of The Rules Governing Substantial Acquisitions of Shares)

Name of acquirer Gartmore Investment Management plc

Beneficial owner, if different (Investments managed on a discretionary
from above basis)

Names of any other persons
acting by agreement or
understanding (see SAR 5)

Company dealt in Osmetech plc

Class of voting shares (eg Ordinary GBP0.001
ordinary shares)

Date of acquisition 22nd March 2006

Number of shares acquired 1,700,000

Number of rights over shares
acquired

Nature of rights over shares

Total holding of voting shares 24,084,657 (18.27%)
(and percentage of total voting
shares in issue)

Total holding of rights over
shares (and percentage of total
voting shares in issue)

Combined total holding (and 24,084,657 (18.27%)
percentage) of voting shares and
rights over shares

Casts a different light on it now.

The threads quiet today, i wonder where our most recent contributors might be??

Am sitting comfortably, still holding onto my OMH shares.

I think this thread needed a dose of realism to inject some proper debate about the future direction of the share price. Opposing views should be welcomed provided that nobody conducts personal vendettas just because they dont agree. I personally dont give a toss if someone calls me a tw@t or something similar, but it hardly adds anything meaningful to the debate.

Can only be a good thing that Gartmore have increased their stake.

Can it? State the ble@ding obvious why don't you.
zzzzzzzzzzzzzzzzzzzz
well you've really added a lot haven't you.
zzzzzzzzzzzzzzzzzzzzz

Sorry DITCHPIG, not going to drop to your level, grown-ups only.

bangersmam,

was busy watching VOG, which is what I bought when I sold my OMH. To date I've gained 14% instead of dropping 30%.

Now if you'll excuse me, I have an appointment to get myself fitted for a new white cane . . .

Yes I'm sure that's what you told the judge.

I continue to hold......if you could read english you would see our posts were about your infantile behaviour.....if anybody reads ADVFN they would see you behave the same way on that thread. My posts from now on are directed to serious traders like Hobbst and Soul traders who have objective views.

Oh I see. Thanks for letting us know.
Pity that yourself and the "serious traders like Hobbst and Soul traders " don't know the first thing about Osmetech its products, statergy or history but as you say you are just "serious traders" such things wouldn't be of interest to you.
Hope you managed to put your shorts out today before something vital got singed.
Still as they say in the Midlands.
Shit on the villa!!!

Osmetech (OMH) are tipped as a good value buy in todays Investors Chronicle.

Hot of the press

http://www.investegate.co.uk/Article.aspx?id=200603271510554570A

Osmetech PLC
27 March 2006


Osmetech plc ('Osmetech' or 'the Company')


The Company was notified on 24rd March that Gartmore Investment Ltd (GIL)
Gartmore Fund Managers Limited (GFM) and Gartmore Global Partners (GGP)
increased its reportable interest in the Company due to the purchase of
1,700,000 ordinary shares of 0.1 pence in Osmetech on the 22nd March 2006 and by
a further 25,000 ordinary shares of 0.1 pence in Osmetech on the 23rd March
2006.

The total holding of 24,109,657 shares comprises the aggregated holdings
controlled by GIL, GFM and GGP and represents approximately 18.29 per cent of
the Company's issued ordinary share capital.








This information is provided by RNS
The company news service from the London Stock Exchange

Looking good!!

Osmetech Plc Launch of eSensor
RNS Number:4965A
Osmetech PLC
28 March 2006



News Release

28 March 2006


Launch of eSensor Cystic Fibrosis Carrier Detection System


Osmetech plc is an international healthcare diagnostics group with two
divisions: Molecular Diagnostics and Critical Care, based on the OPTI range of
blood gas and electrolyte analysis products.


Osmetech Molecular Diagnostics has launched its eSensor Cystic Fibrosis Carrier
Detection (CFCD) test and its eSensor 4800 DNA Detection instrument at the
American College of Molecular Genetics meeting in San Diego, US, on 23-26th
March. Product shipments are expected to commence on schedule during the first
half of 2006.


The eSensor instrument and proprietary consumable system was developed by
Clinical Micro Sensors, Inc. (CMS) which was acquired from Motorola Inc. in July
2005.


eSensor

The eSensor system has the capability to perform relatively complex molecular
tests that require the simultaneous analysis of multiple genetic information.
Combining a universal platform design and a patented advanced electrochemical
detection technology, the eSensor System can detect and identify many different
targets at once.


The technology is protected by a strong intellectual property portfolio
comprising over 70 worldwide patents and has benefited from an investment of
over $100m by Motorola during their period of ownership.



FDA approval

In January 2006 Osmetech received 510(k) clearance from the US Food & Drug
Administration ('FDA') for its eSensor CFCD test and its eSensor 4800 DNA
Detection instrument platform.



This FDA approval is a first for a combined instrument and Cystic Fibrosis assay
consumable which incorporates a microarray with electrochemical detection. The
system qualitatively assesses the carrier status for Cystic Fibrosis for all
adult couples contemplating pregnancy.




In clinical trials, studies were conducted using the eSensor CFCD System
compared to bidirectional DNA sequencing. The method comparison studies tested
a total 486 samples. The eSensor CFCD system concordance with sequencing was
98.6% following repeat testing of samples which gave no-call, or 99.6% for
samples which gave a valid result. The comparison study analyzed 11,178
individual mutations. For all mutations the percent agreement between the
eSensor CFCD system and sequencing was 99.0% following repeat testing of samples
which gave no-call or 99.98% for samples which gave a valid result.



FDA submission pipeline

The combined instrument and microarray consumable is the platform which is being
used for future assay development. The next molecular diagnostics tests targeted
for FDA submission will be for CYP450 which will provide pharmacogenomic
information for better patient care and improved healthcare cost management.



James White, Chief Executive, Osmetech plc said,



'We are delighted to have achieved this important milestone with the launch of
the eSensor CFCD system at the American College of Molecular Genetics meeting in
San Diego. This is another important step in the controlled market release of
our first product to the molecular diagnostic laboratories.



'In the first 8 months of ownership of CMS, Osmetech has secured the first FDA
approval for the eSensor product and also obtained an FDA California State
License to manufacture product. The eSensor has now been launched and shipments
should commence on schedule during the first half of 2006.



'We are building on this excellent progress by continuing discussions with
strategic partners who are looking for cost effective and easy to use
instrumentation and consumables to work with other assays both in the healthcare
and non healthcare markets.



'We expect to be able to further demonstrate the considerable value within our
molecular diagnostics products and intellectual property portfolio in due
course.'


For further information:



Osmetech plc: James White, David Sandilands 020 7849 6027

Madano Partnership: Matthew Moth, Mark Way 020 7593 4000




Background information on Cystic Fibrosis

* With a carrier frequency of one in 25 and an incidence of one in 2,500,
Cystic Fibrosis is the most commonly inherited disease in the North American
Caucasian population.



* The American College of Medical Genetics and the American College of
Obstetricians and Gynaecologists recommended in 2001 that Cystic Fibrosis
carrier testing should be made available for all reproductive couples.



* Currently around one million tests are carried out annually in the US
alone.



* Most current tests are not FDA approved and testing locations are
restricted to those 300 institutions which are CLIA approved for running
complex testing where the testing institution is responsible for regulatory
obligations rather than the diagnostic company.



* The tests carried out in the large central laboratories are performed on
instruments that can cost in the region of US$100,000 and a high throughput
is required to justify the capital cost of the equipment.



* In addition the instruments are operated by qualified technicians capable
of interpreting the results.



* As a result of this each test is relatively expensive with each test
recharged at up to US$400 per test to those small to medium sized hospitals
requesting the tests to be run on their behalf.



This information is provided by RNS
The company news service from the London Stock Exchange
END

Osmetech unit launches Cystic Fibrosis
detection test and sensor

LONDON (AFX) - Osmetech PLC said Osmetech Molecular Diagnostics has launched
its eSensor Cystic Fibrosis Carrier Detection (CFCD) test and its eSensor 4800
DNA Detection instrument, and shipments are expected to commence on schedule
during the first half of 2006.
The eSensor system has the capability to perform relatively complex
molecular tests that require the simultaneous analysis of multiple genetic
information.
newsdesk@afxnews.com
lam

Small update to the header. Another busy month for OMH coming up

Bid up from the off - Plenty of stock being taken on at 22p, looks like another T trade buy is on its way.

Here's the IC take on the company.